Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium

NCT00003133 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT00003133
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003133 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Gemcitabine, Doxorubicin, Then Paclitaxel Plus Cisplatin Adjuvant Chemotherapy After Complete Resection of Locally Advanced Transitional Cell Carcinoma of the Urothelium
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Completed
Start date
September 30, 1997
Completion date
January 31, 2003
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, transitional cell cancer of the renal pelvis and ureter